HHG & Company maintained its stake in shares of Curis, Inc. (NASDAQ:CRIS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The hedge fund owned 152,925 shares of the company’s stock at the end of the fourth quarter. HHG & Company’s holdings in Curis were worth $445,000 at the end of the most recent reporting period.

Curis, Inc. (NASDAQ:CRIS) opened at 1.61 on Friday. Curis, Inc. has a 52-week low of $1.60 and a 52-week high of $3.75. The company’s 50-day moving average is $2.44 and its 200-day moving average is $2.53. The company’s market capitalization is $206.71 million.

Curis (NASDAQ:CRIS) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.04. The business had revenue of $2 million for the quarter, compared to the consensus estimate of $2.82 million. During the same quarter last year, the firm posted ($0.06) EPS. The business’s revenue for the quarter was up 13.6% compared to the same quarter last year. On average, analysts expect that Curis, Inc. will post ($0.50) earnings per share for the current fiscal year.

Several equities analysts have recently weighed in on CRIS shares. Roth Capital dropped their price objective on shares of Curis from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, November 9th. Robert W. Baird reissued a “buy” rating and issued a $7.00 price objective on shares of Curis in a research report on Monday, October 19th. Finally, Zacks Investment Research raised shares of Curis from a “hold” rating to a “buy” rating and set a $3.25 price objective on the stock in a research report on Wednesday, December 9th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Curis presently has an average rating of “Buy” and a consensus target price of $5.31.

In other Curis news, Director Daniel R. Passeri sold 48,900 shares of the business’s stock in a transaction on Wednesday, December 23rd. The shares were sold at an average price of $2.78, for a total transaction of $135,942.00. Following the completion of the sale, the director now owns 198,898 shares in the company, valued at approximately $552,936.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Curis, Inc. (NASDAQ:CRIS) is a biotechnology company. The Company is engaged in the development and commercialization drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Curis’ product pipeline also includes CUDC-427, an orally available, small molecule antagonist of inhibitor of apoptosis (IAP) proteins. CUDC-907 is in Phase I clinical trial stage for the treatment of advanced lymphomas and multiple myeloma, and human epidermal growth factor receptor 2 (HER 2-), estrogen-receptor-positive (ER+) or progesterone-receptor-positive (PR+) breast cancer and NUT midline carcinoma. CUDC-427 is in Phase I clinical trial stage for the treatment of advanced solid tumor and lymphomas. The Company’s PD-L1 antagonist and IRAK4 Inhibitor drug candidates are in preclinical stage of development.

12 Month Chart for NASDAQ:CRIS

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.